A rationale for targeting antithrombotic therapy at the vessel wall: Improved antithrombotic effect and decreased risk of bleeding

Wiener Klinische Wochenschrift

Volumn 111, Issue 3, 1999, Pages 81-89

  Buchanan, Michael R ^a   Brister, Stephanie J ^b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b NONE

Author keywords

13HODE; Dermatan sulfate; Hyperplasia; Intimatan; Surface bound thrombin

Indexed keywords

13 HYDROXYOCTADECADIENOIC ACID; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN III; CYCLIC AMP; DERMATAN SULFATE; DIPYRIDAMOLE; FATTY ACID; GLYCOSAMINOGLYCAN; HEPARIN; ICOSANOID; INTIMATAN; PROCOAGULANT; PROSTAGLANDIN SYNTHASE; THROMBIN; THROMBOXANE A2; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; BLEEDING; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CATALYST; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; REVIEW; THROMBOGENESIS; THROMBOGENICITY;

ANIMALS; DERMATAN SULFATE; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; FIBROMUSCULAR DYSPLASIA; HUMANS; RECURRENCE; THROMBIN;

EID: 0033548188     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. RITA Trial Participants (1993) Coronary angioplasty versus coronary artery bypass surgery: the randomized intervention treatment of angina (RITA) trial. Lancet 341: 573-580
2. Kirklin JW, Naftel DC, Blackstone EH, Pohost GM (1989) Summary of a consensus concerning death and ischemic events after coronary artery bypass grafting. Circulation 79 [Suppl] 1: 181-191
3. Schwartz SM, deBlois D, O'Brien RM (1995) The intima. Soil for atherosclerosis and restenosis. Circulation Res 77: 445-465
4. Strauss BH, Chisholm RJ, Keeley FW, Gotlieb AI, Logan RA, Armstrong PW (1994) Extracellular matrix remodelling after balloon angioplasty in a rabbit model of restenosis. Circulation Res 75: 650-658
5. Chervu A, Moore WS (1990) An overview of intimal hyperplasia. Surgery 171: 433-447
6. Bocan TMA, Guyton JR (1985) Human aortic fibrolipid lesions: progenitor lesions for fibrous plaques, exhibiting early formation of the cholesterol-rich core. Am J Pathol 120: 193-198
7. Chen LB, Buchanan JM (1975) Mitogenic activity of blood components. 1. Thrombin and prothrombin. Proc Natl Acad Sci USA 72: 131-135
8. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 362: 801-809
9. Bretschneider E, Wittpoth M, Weber AA, Blusa E, Schrör K (1997) Thrombin but not thrombin receptor activating peptide is mitogenic for coronary artery smooth muscle cells. Thromb Res 87/5: 493-497
10. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker I, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 331: 496-501
11. Grandaliano G, Choudhury GG, Poptic E, Woodruff K, Barnes JL, Abboud HE (1998) Thrombin regulates PDGF expression in bovine glomerular endothelial cells. J Am Soc Nephrol 9: 583-589
12. 3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation 97: 907-915
13. Alexander RW (1994) Inflammation and coronary artery disease. N Engl J Med 331: 468-469
14. Mallory GA, White PO, Salcedo-Salgar J (1993) The speed of healing of myocardial infarction: a study of the pathologic anatomy in 72 patients. Am Heart J 18: 647-671
15. Mehta JL, Saldeen GP, Rand K (1998) Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 31: 1217-1225
16. Schwartz RS (1998) Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodelling. Am J Cardiol 81 (7A): 14E-17E
17. Cicala C, Cirino G (1997) Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life Sciences 62/20: 1817-1824
18. Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chissolm GM (1995) Restenosis after experimental angioplasty: intimal, medial and adventitial changes associated with constrictive remodeling. Circulation 76: 996-1002
19. Post MJ, Borst C, Kuntz RE (1994) The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty: a study in the normal rabbit and in the hypercholesterolemic Yucatan micropig. Circulation 89: 2816-2821
20. Mintz GS, Douek PC, Bonner RF, Kent KM, Pichard AD, Satler LF, Leon MB (1993) Intravascular ultrasound comparison of de novo and restenotic coronary artery lesions [abst.] J Am Coll Cardiol 21: 118A
21. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrick G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwort H, Colombo A, Bot JJ, Van den Heuvel P, Delcan J, Morel M (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 331: 489-495
22. Coats WD, Whittaker P, Cheung DT, Currier JW, Han B, Faxon DP (1997) Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Circulation 95: 1293-1300
23. Frid MG, Dempsey EC, Durmowicz AG, Stenmark KR (1997) Smooth muscle cell heterogeneity in pulmonary and systemic vessels. Arterioscler Thromb Vasc Biol 17: 1203-1209
24. Myers PR, Tanner MA (1998) Vascular endothelial cell regulation of extracellular matrix collagen: role of nitric oxide. Arterioscler Thromb Vasc Biol 18: 717-722
25. Buchanan MR, Brister SJ (1998) Inhibition of chronic vessel wall (re)stenosis with acute thrombin inhibition: Relative effects of heparin and dermatan sulphate. Thromb Res (in press)
26. Capron L, Jarnet J, Heudes D, Joseph-Monrose D, Bruneval P (1997) Repeated balloon injury of rat aorta: a model of neointima with attenuated inhibition by heparin. Arterioscler Thromb Vasc Biol 17: 1649-1656
27. Antoniucci D, Valenti R, Santoro GM, Bolognese L, Trapani M, Cerisano G, Boddi B, Fazzini PF (1998) Restenosis after coronary stenting in current clinical practice. Am Heart J 135: 510-518
28. Channon KM, Fulton GJ, Davies MG, Peters KG, Ezekowitz MD, Hagen P-O, Annex BH (1997) Modulation of tissue factor protein expression in experimental venous bypass grafts. Arterioscler Thromb Vasc Biol 17: 1313-1319
29. McGee MP, Teuschler H, Parthasarathy N, Wagner WD (1995) Specific regulation of procoagulant activity on monocytes. J Biol Chem 270/44: 26109-26115
30. McBane RD, Miller RS, Hassiriger NL, Chesebro JG, Nemerson Y, Owen WG (1997) Tissue prothrombin: universal distribution in smooth muscle. Arterioscler Thromb Vasc Biol 17: 2430-2436
31. DiCorleto PE, Bowen-Pope DF (1983) Cultured endothelial cells produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 80: 1919-1923
32. 2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 96: 2280-2286
33. Ghigliotti G, Waissbluth AR, Speidel C, Abendschein DR, Eisenberg PR (1998) Prolonged activation of prothrombin on the vascular wall after arterial injury. Arterioscler Thromb Vasc Biol 18: 250-257
34. Castellot JJ Jr, Beeler DL, Rosenberg RD, Karnovsky MJ (1984) Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol 58: 315-320
35. Clowes AW, Clowes MM (1986) Kinetics of cellular proliferation after arterial injury: heparin inhibits rat smooth muscle mitogenesis and migration. Circulation Res 58: 839-845
36. Ferrell M, Fuster V, Gold HK, Chesebro JH (1992) A dilemma for the 1990's: Choosing appropriate experimental animal models for the prevention of restenosis. Circulation 85: 1630-1631
37. Hanke H, Oberhoff M, Hanke S, Hassenstein S, Kamenez J, Schmidt KM, Betz E, Karsch KR (1992) Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin. Circulation 85: 1548-1556
38. Okwusidi JI, Anvari N, Kulczycky M, Blajchman MA, Buchanan MR, Ofosu FA (1991) Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. J Lab Clin Med 117: 359-364
39. Okwusidi JI, Falcone M, Van Ryn-McKenna J, Ofosu FA, Buchanan MR (1990) In vivo catalysis of thrombin inhibition by antithrombin III and heparin co-factor II and antithrombotic effect: differential effects of dermatan sulfate and unfractionated heparin. Thromb Haemorrh Dis 2: 17-23
40. Hogg PJ, Jackson CM (1989) Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 86: 619-623
41. Bar-Shavit R. Eldor A. Vlodavsky I (1989) Binding of thrombin to subendothelial extracellular matrix. J Clin Invest 84: 1098-1104
42. Brister SJ, Ofosu FA, Buchanan MR (1993) Thrombin generation during cardiac surgery. Is heparin the ideal anticoagulant? Thromb Haemost 70: 259-263
43. Wells J, Nicosia S, Wale C, Smith LJ, Buchanan MR (1994) Thrombin generation in patients undergoing carotid endarterectomy: Implications in acute vessel wall closure and antithrombotic therapy. Thromb Res 75: 419-426
44. Gill JB, Holder DA, Brister SJ, Ofosu FA, Buchanan MR (1993) Thrombin generation post PTCA following cessation of heparin infusion. Can J Cardiol 9(E): 84E
45. Geary RL, Koyama N, Wang TW, Vergel S, Clowes AW (1995) Failure of heparin to inhibit intimal hyperplasia in injured baboon arteries: the role of heparin-sensitive and insensitive pathways in the stimulation of smooth muscle cell migration and proliferation. Circulation 91: 2972-2981
46. Buchanan MR, Boneu B, Ofosu FA, Hirsh J (1985) The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 65: 198-201
47. Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR (1989) The effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci 566: 304-312
48. Brister SJ, Ofosu FA, Heigenhauser GFJ, Gianese F, Buchanan MR (1994) Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice. Thromb Haemost 71: 468-473
49. Buchanan MR, Brister SJ (1998) Surface-bound thrombin inhibition and intimai hyperplasia following vessel wall injury. Proc 15th Int' Congr Thromb. Antalya, Turkiye, Oct 16
50. Aspirin Trialists' Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 308: 159-168
51. Buchanan MR, Brister SJ (1995) Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 11: 317-321
52. Grotemeyer K-H, Scharafinski H, Husstedt I-W (1993) Two year follow up of aspirin responders and non-responders. A pilot study including 180 post stroke patients. Thromb Res 71: 397-403
53. Mueller MR, Salat A, Stangl P, Muabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E (1997) Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78: 1003-1007
54. Buchanan MR, Brister SJ (1996) Chronic restenosis can be attenuated by acute antithrombotic treatment at the time of injury: Implications in (cardio)vascular procedures. Haemostasis 23 [Suppl] 3: 23
55. Buchanan MR, Brister SJ, Peniston C, Swartz L, Leclerc Y, Bourassa MG for the BRAT Investigators (1997) There is no rationale for stopping aspirin before cardiac surgery. Thromb Haemost 76 [Suppl]
56. The EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336: 1689-1696
57. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338: 1498-1505
58. Sirois MG, Simons M, Kuter DJ, Rosenberg RD, Edelman ER (1997) Rat arterial wall retains myointimal hyperplastic potential long after arterial injury. Circulation 96: 1291-1298
59. 2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomized placebo controlled trial. Br Heart J 71: 7-12
60. Zerkowski H-R, Knocks M, Konerding MA, Doetsch N, Roth G, Hakim K, Reidemeister JC (1993) Endothelial damage of the venous graft in CABG: influence of solutions used for storage and rinsing on endothelial function. Eur J Cardio-Thoracic Surg 7: 376-382
61. The GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673-682
62. Buchanan MR, Haas T, Lagarde M, Guichardant M (1985) 13-Hydroxy-octadecadienoic acid is the vessel wall chemorepellant factor, LOX. J Biol Chem 260: 16056-16059
63. Haas TA, Bertomeu M-C, Bastida E, Buchanan MR (1990) Cyclic AMP regulation of endothelial cell triglyceride turnover, 13-hydroxyoctadecadienoic acid (13-HODE) synthesis and endothelial cell thrombogenicity. Biochim Biophys Acta 1031: 174-178
64. Weber E, Haas TA, Mueller TH, Eisert WG, Hirsh J, Buchanan MR (1990) Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury. Influence of salicylate and dipyridamole treatment. Thromb Res 57: 383-392
65. Bertomeu M-C, Crozier GL, Haas TA, Fleith M, Buchanan MR (1990) Selective effects of dietary fats on vascular 13-HODE synthesis and platelet/vessel wall interactions. Thromb Res 59: 819-830
66. Brister SJ, Haas TA, Bertomeu M-C, Austin J, Buchanan MR (1990) 13-HODE synthesis in internal mammary arteries and saphenous veins: Implications in cardiovascular surgery. Adv Prost Thromb Leuko Res 21: 667-670
67. Buchanan MR, Brister SJ (1994) Increasing vessel wall (VW) 13HODE metabolism with dietary fatty acid supplements in patients undergoing cardiac surgery decreases VW reactivity to platelets. Can J Cardiol 10 [Suppl C]: 67C
68. Buchanan MR, Horsewood P, Brister SJ (1998) Regulation of endothelial cell/and platelet/receptor-ligand binding by the 12- and 15-lipoxygenase monohydroxides, 12-, 15-HETE and 13HODE. Prost Leuko Essential Fatty Acids 58: 339-346
69. Iimura O, Kusano E, Amemiya M, Muto S, Ikeda U, Shimada K, Asano Y (1996) Dipyridamole enhances interleukin-1β-stimulated nitric oxide production by cultered rat vascular smooth muscle cells. Eur J Pharm 296: 319-326
70. Peracchia R, Tamburro A, Prontera C, Mariani B, Rotilio D (1997) cAMP involvement in the expression of MMP-2 and MT-MMP1 metalloproteinases in human endothelial cells. Arterioscler Thromb Vasc Biol 17: 3185-3190
71. Yasukawa H, Imaizumi T, Matsuoka H, Nakashima A, Morimatus M (1997) Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1. Circulation 95:1515-1522
72. Turek JJ, Li Y, Schoenlein IA, Allen KGD, Watkins BS (1998) Modulation of macrophage cytokine production by conjugated linoeic acids is influenced by dietary n-6:n-3 fatty acid ratio. J Nutr Biochem 9: 258-266
73. 2-integrin mediated cell attachment to ICAM-1. Eur J Immunol 28: 433-443
74. Golino P, Ambrosia G, Ragni M, Cirillo P, Esposito N, Willerson JT, Rothlein R, Petrucci L, Condorelli M, Chiariello M, Buja LM (1997) Inhibition of leucocyte and platelet adhesion reduces neointimal hyperplasia after arterial injury. Thromb Haemost 77/4: 783-788
75. Ammon C, Kreutz, Rehli M, Krause SW, Andreesen R (1998) Platelets induce monocyte differentiation in serum-free coculture. J Leukoc Biol 63: 469-476
76. Lee S, Felts KA, Parry GC, Armacost LM, Cobb RR (1997) Inhibition of 5-lipoxygenase blocks IL-1β-induced vascular adhesion molecule-1 gene expression in human endothelial cells. J Immunol 158: 3401-3407
77. Allan G, Bhattacherjee P, Brook CD, Read NG, Parke AJ (1985) Myeloperoxidase activity as a quantitative marker of polymorphonuclear leukocyte accumulation into an experimental myocardial infarct - The effect of Ibuprofen on infarct size and polymorphonuclear leukocyte accumulation. J Cardiovasc Pharmacol 7: 1154-1160
78. Van de Velde MJ, Engels F, Henricks PAJ, Bloemen PGM, Nijkamp FP (1995) The linoleic acid metabolite 13-HODE modulates degranulation of human polymorphonuclear leukocytes. FEBS Letters 369: 301-304
79. Nageh MR, Sandber ET, Marotti KR, Lin AH, Melchior EP, Bullard DC, Beaudet AL (1997) Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 17: 1517-1520
80. 1 protects against ischemia reperfusion injury of the liver by inhibition of neutrophil adherence to endothelial cells. Transplantation 64/11: 1514-1520
81. Williams DO (1998) Radiation vascular therapy: a novel approach to preventing restenosis. Am J Cardiol 81/7A: 18E-20E
82. Rubin P, Williams JP, Riggs PN, Bartos S, Sarac T, Pomerantz R, Castano J, Schell M, Green RM (1998) Cellular and molecular mechanisms of radiation inhibition of restenosis. Part I: Role of the macrophage and platelet-derived growth factor. Int J Radiation Oncology Biol Phys 40: 929-941
83. Panek RL, Dahring TK, Olszewski BJ, Keiser JA (1997) PDGF receptor protein tyrosine kinase expression in the balloon-injured rat carotid artery. Thromb Vasc Biol 17: 1283-1288
84. Kipshidze N, Sahota H, Komorowski R, Nikolaychik V, Keelan MH (1998) Photoremodeling of arterial wall reduces restenosis after balloon angioplasty in an atherosclerotic rat model. J Am Coll Cardiol 31: 1152-1157
85. Buchanan MR (1989) Inhibition of thrombosis by leukocytes: role of endogenous fatty acid metabolites. Sanofi Fdn Thromb Res Bull 4: 14-22
86. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, Kuhn H, Buevara NV, Chan L (1996) Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 98: 2201-2208
87. Cerletti C, Ebangelista V, De Gaetano G (1992) Polymorphonuclear leucocyte-dependent modulation of platelet function: relevance to the pathogenesis of thrombosis. Pharmacol Res 26/3: 261-268
88. Shen J, Kuhn H, Petho-Schramm A, Chan L (1995) Transgenic rabbits with the integrated human 15-lipoxygenase gene driven by a lysozyme promoter: macrophage-specific expression and variable positional specificity of the transgenic enzyme. FASEB J 9: 1623-1631
89. 1 which inhibits vascular smooth muscle cell proliferation. J Nutr 127: 1765-1771